20 citations
,
December 2010 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”
Decreased CD200 in hairfollicles may cause immune issues in some alopecia areata cases.
Hairfolliclestemcells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
Hairfollicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.
PP405, a topical LDH inhibitor, has shown to stimulate hairfolliclestemcell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.